EUVIMEDEUVIMED entdecken
Crossref

STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer

Xiao Wang iD, Yueqin Zhang, Anan Li, Chuanzan Zhou, Sen Xu, Zongting Gu, Wei Wang, Peng Nan, Ran Tao

Journal of Gastroenterology · 2025

DOI: 10.1007/s00535-025-02291-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastroenterology, 2025. Verfasst von Xiao Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: General Surgery, Cancer Center, Department of Hepatobiliary and Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospi…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Immune Checkpoint Inhibitors. Die Arbeit nennt 55 Literaturangaben. Gefördert von: Medical Science and Technology Project of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with limited treatment options. Immunotherapy, though effective in various tumors, has limited efficacy in PDAC due to immune tolerance. Thus, identifying new targets to enhance immunotherapy response is crucial. METHODS: This study used bioinformatics analysis and public database data to identify STYK1 as a potential PDAC biomarker. We analyzed STYK1 expression in PDAC tissues, its link to patient prognosis and immune cell infiltration. In vitro experiments assessed the impact of STYK1 knockdown on PDAC cell proliferation, migration, and invasion. Immunohistochemical analysis was performed on 79 PDAC tissue samples to evaluate CD8+ T cell infiltration. In vivo studies examined the effects of STYK1 knockdown on tumor growth, T cell infiltration and activation, especially with anti-PD-L1 antibodies. We also investigated the molecular mechanisms of STYK1's regulation of T cell infiltration, focusing on its association with CCL20 and its role beyond the PD-1/PD-L1 pathway. RESULTS: Elevated STYK1 expression in PDAC tissue is associated with poor prognosis and reduced CD8+ T cell infiltration. STYK1 knockdown inhibits PDAC cell proliferation, migration, and invasion in vitro. In vivo, it decreases tumor growth and, when combined with anti-PD-L1 antibody treatment, significantly enhances T cell infiltration and activation without affecting PD-L1 expression. STYK1 regulates T cell infiltration via CCL20, independently of the PD-1/PD-L1 signaling pathway. CONCLUSIONS: STYK1 is a potential predictive biomarker for immunotherapy response in PDAC, as its regulation of T cell infiltration via CCL20, independent of the PD-1/PD-L1 pathway, may provide a strategy to potentially augment immunotherapy efficacy, pending mechanistic confirmation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalImmune Checkpoint InhibitorsHumansAnimalsCell ProliferationCD8-Positive T-LymphocytesMiceCell Line, TumorBiomarkers, TumorCell MovementB7-H1 AntigenPrognosisFemaleMaleLymphocytes, Tumor-InfiltratingGene Knockdown TechniquesImmunotherapy

Stichwörter der Autor:innen

BioinformaticsImmune infiltrationImmunotherapyPancreatic cancerSTYK1

Substanzen

Biomarkers, TumorB7-H1 AntigenImmune Checkpoint InhibitorsCD274 protein, human

Autor:innen und Institutionen

  • General Surgery, Cancer Center, Department of Hepatobiliary and Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou,…
  • Urology and Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
  • Second Clinical Medical School, Zhejiang Chinese Medical University, Hangzhou, China.
  • Shanghai Jiaotong University School of Medicine, Punan Branch of Renji Hospital, Shanghai, China.
  • Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China. nanpeng_01@163.com.

ORCID-Profile: Xiao Wang

Förderung

  • Medical Science and Technology Project of Zhejiang Province

Zitieren

APA

Wang, X., Zhang, Y., Li, A., Zhou, C., Xu, S., Gu, Z., Wang, W., Nan, P., & Tao, R. (2025). STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer. Journal of Gastroenterology. https://doi.org/10.1007/s00535-025-02291-3

Vancouver

Wang X, Zhang Y, Li A, Zhou C, Xu S, Gu Z, et al. STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer. Journal of Gastroenterology. 2025. doi:10.1007/s00535-025-02291-3

BibTeX
@article{Wang2025,
  author = {Wang, Xiao and Zhang, Yueqin and Li, Anan and Zhou, Chuanzan and Xu, Sen and Gu, Zongting and Wang, Wei and Nan, Peng and Tao, Ran},
  title = {STYK1 as a targetable vulnerability enhances the efficacy of anti-PD-L1 therapy in pancreatic cancer},
  journal = {Journal of Gastroenterology},
  year = {2025},
  doi = {10.1007/s00535-025-02291-3}
}
Kostenlos starten →